Dr. Thorsten Schmidt joined Sanofi in 2002. He is currently the Head of the German Biologics Research Platform in the area of protein therapeutics. He is in this role since 2016 and responsible for a team of 60 scientists working on the design, the production and the analysis of next-generation bio-therapeutics. Prior to this role he was a heading a team of scientist in the disease area diabetes (GI Endocrinology) and responsible for assay development and High Throughput Screening (HTS) activities for Kinases, GPCRs and Ion channels.
Dr. Thorsten Schmidt studied Human Biology and received his Ph. D. degree in Biochemistry and Molecular Biology from the University of Marburg. He pursued his post-doctoral training at the university hospital in Essen and started his industrial career at Bayer AG in 1999 in the Infectious Disease unit.